Cytoprotective IgG Antibodies in Sera from a Subset of Patients with AQP4‑IgG Seropositive Neuromyelitis Optica Spectrum Disorder

Single Donor Human Complement Serum from Innovative Research was used in the following study:

Cytoprotective IgG Antibodies in Sera from a Subset of Patients with AQP4‑IgG Seropositive Neuromyelitis Optica Spectrum Disorder

LukmaneeTradtrantip, Michael R. Yeaman & A. S. Verkman

Scientific Reports
November 9, 2021

Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disorder that attacks the central nervous system and can cause demyelination in the optic nerve, spinal cord, and brain, and potentially cause further neurological deficits. Over 70% of patients suffering from NMOSD are seropositive for IgG autoantibodies which target extracellular epitopes of astrocyte water channel aquaporin-4 (AQP4), and these autoantibodies are called AQP4-IgG.

Evidence from multiple studies supports the theory that AQP4-IgG is pathogenic in seropositive NMOSD by binding to AQP4 and activating complements, causing complement-dependent cellular injury among other neurological disruptions. Researchers in this study found a significant portion of patients with NMOSD possessed naturally cytoprotective sera against AQP4-IgG and sought to discover and characterize the mechanisms behind it.

Related products available from Innovative Research also include:

Pooled Human Complement Serum

Pooled Human Serum Off The Clot

Single Donor Human Plasma (Blood Derived)